Andreas duBois

1.2k total citations
15 papers, 713 citations indexed

About

Andreas duBois is a scholar working on Oncology, Reproductive Medicine and Cancer Research. According to data from OpenAlex, Andreas duBois has authored 15 papers receiving a total of 713 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 7 papers in Reproductive Medicine and 4 papers in Cancer Research. Recurrent topics in Andreas duBois's work include Ovarian cancer diagnosis and treatment (7 papers), Cancer Treatment and Pharmacology (5 papers) and Breast Cancer Treatment Studies (3 papers). Andreas duBois is often cited by papers focused on Ovarian cancer diagnosis and treatment (7 papers), Cancer Treatment and Pharmacology (5 papers) and Breast Cancer Treatment Studies (3 papers). Andreas duBois collaborates with scholars based in Germany, France and United Kingdom. Andreas duBois's co-authors include Christian Marth, Jonathan A. Ledermann, Tate Thigpen, Henry C Kitchener, Edward L. Trimble, Monica Bacon, Gavin Stuart, Michael Friedländer, Barbara Schmalfeldt and Jens Huober and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Andreas duBois

14 papers receiving 700 citations

Peers

Andreas duBois

ONCOL

SURGE

Noriko Seki Japan

Donna Stock-Novack United States

Tomoyuki Kusumoto Japan

Laura Attademo Italy

Joseph J. Kash United States

Casey Cosgrove United States

I. L. Ray-Coquard France

Katrin Hefler‐Frischmuth Austria

James Kauderer United States

Geraldine Goss Australia

Noriko Seki Japan

Andreas duBois

266 ×0.7

332 ×1.1

ONCOL

108 ×0.6

SURGE

449 ×3.6

210 ×1.9

Citations per year, relative to Andreas duBois Andreas duBois (= 1×) peers Noriko Seki

Countries citing papers authored by Andreas duBois

Since Specialization

Citations

This map shows the geographic impact of Andreas duBois's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas duBois with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas duBois more than expected).

Fields of papers citing papers by Andreas duBois

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas duBois. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas duBois. The network helps show where Andreas duBois may publish in the future.

Co-authorship network of co-authors of Andreas duBois

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas duBois. A scholar is included among the top collaborators of Andreas duBois based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas duBois. Andreas duBois is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Mirza, Mansoor Raza, Bradley J. Monk, Amit M. Oza, et al.. (2016). gynaecological cancers A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of Oncology. 27. vi568–vi568. 7 indexed citations

Butts, Charles, Suzanne Kamel‐Reid, Gerald Batist, et al.. (2013). Benefits, Issues, and Recommendations for Personalized Medicine in Oncology in Canada. Current Oncology. 20(5). 475–483. 22 indexed citations

Bauerschlag, Dirk, Felix Hilpert, Werner Meier, et al.. (2013). Evaluation of Potentially Predictive Markers for Anti-Angiogenic Therapy with Sunitinib in Recurrent Ovarian Cancer Patients. Translational Oncology. 6(3). 305–310. 10 indexed citations

Stuart, Gavin, Henry C Kitchener, Monica Bacon, et al.. (2011). 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer. International Journal of Gynecological Cancer. 21(4). 750–755. 314 indexed citations

Fotopoulou, Christina, Andreas duBois, Alexandros N. Karavas, et al.. (2008). Incidence of Venous Thromboembolism in Patients With Ovarian Cancer Undergoing Platinum/Paclitaxel–Containing First-Line Chemotherapy: An Exploratory Analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Journal of Clinical Oncology. 26(16). 2683–2689. 74 indexed citations

duBois, Andreas, Jens Huober, S. Loibl, et al.. (2006). Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum–taxane based therapy—A phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)☆. Gynecologic Oncology. 105(1). 132–137. 67 indexed citations

Jackisch, Christian, et al.. (2006). Paclitaxel-carboplatin-gemcitabine (TCG) versus paclitaxel-carboplatin (TC) as first line treatment in women with ovarian cancer: A randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102). Geburtshilfe und Frauenheilkunde. 66(S 01). 1 indexed citations

Reinartz, Silke, H. Schlebusch, Jens Huober, et al.. (2004). Vaccination of Patients with Advanced Ovarian Carcinoma with the Anti-Idiotype ACA125. Clinical Cancer Research. 10(5). 1580–1587. 97 indexed citations

Pollow, K., Winfried Schoenegg, Heinz Koelbl, et al.. (2004). Safety and tolerability of adjuvant exemestane plus goserelin with or without tibolone in receptor-positive, node-negative primary breast cancer in premenopausal women: The final results of the randomized multicenter ADAGIO pilot study. Journal of Clinical Oncology. 22(14_suppl). 594–594. 3 indexed citations

10.

Martín, Miguel, M. Spielmann, M Namer, et al.. (2003). Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. Annals of Oncology. 14(8). 1246–1252. 40 indexed citations

11.

Spielmann, M., Miguel Martín, Moïse Namer, et al.. (2001). Activity of Pemetrexed (ALIMTA®, Multitargeted Antifolate, LY231514) in Metastatic Breast Cancer Patients Previously Treated with an Anthracycline and a Taxane: An Interim Analysis. Clinical Breast Cancer. 2(1). 47–51. 44 indexed citations

12.

Lück, Hans‐Joachim, Christoph Thomssen, Andreas duBois, et al.. (1996). Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.. PubMed. 23(1 Suppl 1). 33–6. 21 indexed citations

13.

duBois, Andreas, et al.. (1996). Clinical course and management of paclitaxel extravasation. Oncology Reports. 3(5). 973–974. 7 indexed citations

14.

duBois, Andreas, et al.. (1995). CISPLATIN-INDUCED ALTERATIONS OF SEROTONIN METABOLISM IN PATIENTS WITH OR WITHOUT EMESIS FOLLOWING CHEMOTHERAPY. Oncology Reports. 2(5). 839–842. 5 indexed citations

15.

duBois, Andreas & P Vanderhoeft. (1970). [Pulmonary exeresis for bronchial cancer: a study of the survival of 120 patients].. PubMed. 69(5). 337–47. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact